ArticleAbdominal radiology (New York)2026
Radiofrequency ablation is safe in patients with hepatocellular carcinoma and thrombocytopenia.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Determinants of thrombocytopenia in critically ill patients: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to evaluate the safety and efficacy of radiofrequency ablation (RFA) in cirrhotic patients with hepatocellular carcinoma (HCC) and severe thrombocytopenia (platelet count < 50 × 10⁹/L).
methodsA retrospective analysis was conducted on 166 cirrhotic HCC patients who underwent RFA (Jan 2017 to Jan 2024). Patients were categorized into three groups based on preoperative platelet counts: Group A (≤ 30 × 10⁹/L), Group B (31-49 × 10⁹/L), and Group C (≥ 50 × 10⁹/L). The primary outcome was perioperative major hemorrhage. Secondary outcomes included postoperative complications, overall survival (OS), and tumor response.
resultsPerioperative major hemorrhage occurred in 2.4% of patients (4/166), all in Group C (P = 0.287). Postoperative complications developed in 10.8% of cases (18/166), with comparable rates across groups (P = 0.95). The 90-day mortality rate was 1.8% (3/166), showing no intergroup difference (P = 0.304). Survival outcomes were similar among groups, with 1-/3-year survival rates of 100.0%/85.7% (Group A), 96.2%/88.1% (Group B), and 94.6%/84.4% (Group C) (P = 0.633). Tumor response rates did not differ significantly (P = 0.817), with complete response achieved in 83.3% of evaluable cases (135/162).
conclusionRFA is safe and effective for cirrhotic HCC patients with severe thrombocytopenia (< 50 × 10⁹/L), supporting the SIR guideline-recommended platelet threshold of > 30 × 10⁹/L for this high-risk population. CLINICAL SIGNIFICANCE: RFA demonstrates high efficacy and safety in cirrhotic patients with HCC, even those with severe thrombocytopenia (< 50 × 10⁹/L). These findings not only validate the SIR guideline-recommended platelet threshold (> 30 × 10⁹/L) but also expand therapeutic options for this high-risk population.
Indexed as
Identifiers
40748458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.